Introduktion

Abametapir (CAS 1762-34-1) is a remarkable pharmaceutical compound that has gained significant attention in recent years as an effective treatment for head lice infestations. This compound, also known by its chemical name 5,5′-Dimethyl-2,2′-dipyridyl or HA-44, represents a breakthrough in pediatric parasitic treatment. Originally developed as a building block for chemical synthesis, abametapir has emerged as a potent insecticidal agent with a unique mechanism of action that sets it apart from traditional lice treatments.

In July 2020, the U.S. Food and Drug Administration (FDA) approved abametapir as the active ingredient in Xeglyze Lotion, marking a significant advancement in the treatment of head lice infestations, particularly for children as young as 6 months old. This approval came at a crucial time, as resistance to traditional over-the-counter treatments has become increasingly common.

What is Abametapir?

Abametapir is a synthetic chemical compound that belongs to the bipyridine family. It is classified as a metalloproteinase inhibitor and possesses potent insecticidal properties, specifically targeting head lice (Pediculus humanus capitis). The compound works by inhibiting metalloproteinase enzymes that are essential for the survival and development of lice eggs (nits).

What makes abametapir particularly valuable is its ovicidal activity—it is effective against lice eggs at various stages of development, including those that have developed resistance to traditional treatments like permethrin and DDT. Studies have shown that abametapir maintains efficacy against resistant strains, making it a crucial option for families struggling with persistent infestations.

Chemical Properties and Specifications

Property	Værdi
CAS-nummer	1762-34-1
Molekylær formel	C12H12N2
Molekylvægt	184.24 g/mol
Chemical Name	5,5′-Dimethyl-2,2′-dipyridyl
Synonymer	6,6′-Bi-3-picoline, HA-44, BRN 0123183
Udseende	White to off-white crystalline solid
Renhed	≥98%
Opløselighed	Soluble in organic solvents

Virkningsmekanisme

Abametapir’s effectiveness against head lice stems from its ability to inhibit metalloproteinase enzymes. These enzymes play a critical role in the biological processes of lice, particularly in:

• Egg Development: Metalloproteinases are essential for the proper development of lice eggs, and inhibition prevents viable eggs from maturing into nymphs.
• Louse Survival: The compound disrupts critical physiological processes in adult lice, leading to their death.
• Egg Hatching: By interfering with the enzymes required for hatching, abametapir breaks the life cycle of lice.

Unlike traditional neurotoxin-based treatments that target the nervous system of lice, abametapir’s enzyme inhibition approach works through a different pathway, making it effective against lice that have developed resistance to pyrethroid-based products.

FDA Approval and Clinical Use

Xeglyze Lotion

Abametapir received FDA approval on July 24, 2020, under the brand name Xeglyze Lotion, manufactured by Dr. Reddy’s Laboratories. The approval was specifically for the treatment of head lice infestation in patients aged 6 months and older.

This was the first new FDA-approved topical treatment for head lice in decades, representing a major advancement in pediatric dermatology. The approval was based on clinical trials demonstrating both safety and efficacy in treating infestations, including those caused by pesticide-resistant lice.

Key Advantages

• Single Application: Unlike many treatments requiring multiple applications, abametapir typically requires just one application.
• Age Approval: Safe for use in infants as young as 6 months, a critical advantage for families with young children.
• Resistance Management: Effective against permethrin-resistant and DDT-resistant lice strains.
• Ovicide Activity: Targets both adult lice and eggs, breaking the infestation cycle.

Industrial and Research Applications

Beyond its pharmaceutical applications, abametapir serves as an important building block in chemical synthesis and research:

Chemical Synthesis

• Coordination Chemistry: Abametapir is used in the synthesis of lanthanide coordination complexes. These complexes have shown promising antifungal activity against Candida albicans.
• Antibacterial Research: The compound has been used in developing divalent vancomycin derivatives with enhanced antibacterial activity against vancomycin-resistant enterococci (VRE).
• Ligand Development: As a bipyridine derivative, it serves as a ligand in various organometallic and coordination compound syntheses.

Research Applications

Scientists continue to explore abametapir’s potential in various therapeutic areas. Its metalloproteinase inhibition properties make it a subject of interest in studying enzyme-related physiological processes and developing novel therapeutic agents.

Toxicology and Safety Profile

Understanding the safety profile of abametapir is essential for its proper handling and use:

Toxicological Data

• Acute Toxicity (Mouse, IP): LD50 = 225 mg/kg
• Formulation Safety: The topical formulation (Xeglyze Lotion) contains benzyl alcohol as an excipient.
• Special Populations: Caution is advised for use in neonates and low birth weight infants due to historical associations with benzyl alcohol exposure.

Sikkerhedsforanstaltninger

• For Pharmaceutical Use: Follow prescribed dosage and application instructions carefully.
• For Research/Industrial Handling: Use appropriate PPE including gloves, safety goggles, and lab coat.
• Opbevaring: Store in a cool, dry place away from direct sunlight.
• Disposal: Dispose of in accordance with local regulations for pharmaceutical and chemical waste.

Usage Guidelines

For Head Lice Treatment

When used as prescribed (Xeglyze Lotion):

1. Apply to dry hair and scalp, covering all areas thoroughly.
2. Leave in for 10 minutes.
3. Rinse thoroughly with water.
4. Use a fine-toothed comb to remove dead lice and eggs.
5. A single application is typically sufficient.

For Research Applications

Follow standard laboratory protocols for chemical handling. Consult safety data sheets (SDS) before working with abametapir in research settings.

Frequently Asked Questions

Q: How does abametapir differ from traditional lice treatments?

A: Unlike pyrethroid-based treatments (like permethrin) that target the nervous system, abametapir works by inhibiting metalloproteinase enzymes. This makes it effective against lice that have developed resistance to traditional treatments.

Q: Is abametapir safe for children?

A: Yes, abametapir (as Xeglyze Lotion) is FDA-approved for use in patients aged 6 months and older. However, always follow the prescribing information and consult a healthcare provider.

Q: Can abametapir treat resistant lice?

A: Yes, studies have shown that abametapir is effective against DDT-resistant and permethrin-resistant head lice strains, making it a valuable option for difficult-to-treat infestations.

Q: What is the molecular weight of abametapir?

A: The molecular weight of abametapir (C12H12N2) is 184.24 g/mol.

Q: Does abametapir kill lice eggs?

A: Yes, abametapir has ovicidal activity and is effective against lice eggs at various developmental stages (0-2, 3-5, and 6-8 days old).

Why Choose Our Abametapir Product?

1. High Purity: Our abametapir meets or exceeds ≥98% purity standards.
2. Quality Assured: Every batch is tested to ensure consistent quality and reliability.
3. Competitive Pricing: Cost-effective solutions for both research and pharmaceutical applications.
4. Technical Support: Our team provides comprehensive technical support and documentation.
5. Reliable Supply: Consistent availability for your ongoing research and development needs.

Konklusion

Abametapir (CAS 1762-34-1) represents a significant advancement in the treatment of head lice infestations. With its unique mechanism of action as a metalloproteinase inhibitor and FDA approval for use in patients as young as 6 months, it offers hope for families struggling with treatment-resistant lice. Beyond its pharmaceutical applications, abametapir continues to serve as a valuable building block in chemical research, particularly in the development of novel coordination compounds with antifungal and antibacterial properties.

Whether you are a healthcare provider seeking effective treatment options, a researcher studying metalloproteinase inhibitors, or a pharmaceutical company looking for high-quality chemical inputs, abametapir offers a proven solution backed by scientific research and regulatory approval.